Erdafitinib作为晚期转移性尿路上皮癌二线治疗的经济评估：来自美国的真实世界数据和来自中国的前瞻性分析
本数据集包含Erdafitinib作为晚期转移性尿路上皮癌二线治疗的成本效果分析数据，涵盖美国和中国视角的Markov模型参数与结果。
基本信息
资源简介
Erdafitinib作为晚期转移性尿路上皮癌二线治疗的经济评估：来自美国的真实世界数据和来自中国的前瞻性分析
【一句话概览】
本数据集是 figshare 公开的结构化表格数据集，收录 2 个文件、合计 218.56 KB，主题涵盖 Erdafitinib、metastatic urothelial carcinoma、cost-effectiveness、United States、China，可用于统计建模、特征工程与队列分析，CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China》。配套论文《Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China》发表于 Future Oncology（2025），DOI：10.1080/14796694.2025.2504321。项目资助方：This manuscript was funded by National Natural Science Foundation of China (grant number 71874209); the research project of the Health Commission of Hunan province (grant number 202113050283);the Fundamental Research Funds for the Central Universities of Central South University (grant number 2023ZZTS0924); Hunan Provincial Natural Science Foundation of China (grant number 2023JJ60503). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.。源站首次发布：2025-05-10。
【数据内容】
源站原始描述：Metastatic urothelial carcinoma (mUC) is challenging to treat, with 37% of patients failing first-line therapy. Effective second-line treatments, like Erdafitinib, are crucial. This study evaluates the cost-effectiveness of Erdafitinib as a second-line treatment for mUC from US and Chinese payer perspectives. A Markov model was developed to project costs, life years, and quality-adjusted life years (QALYs) over lifetime. Data were collected from December 2023 to December 2024 for up-to-date esti…
【数据结构与技术规格】
文件数 2 个，合计 218.56 KB。ifon_a_2504321_sm2014.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，27.52 KB。数据集 DOI：10.6084/m9.figshare.29003801.v1。
【主题与分类】
源站学科分类：Medicine、Pharmacology、Sociology、Cancer、Science Policy。主题标签：Erdafitinib、metastatic urothelial carcinoma、cost-effectiveness、United States、China。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面：https://tandf.figshare.com/articles/dataset/Economic_evaluation_of_Erdafitinib_as_a_second-line_treatment_for_advanced_metastatic_urothelial_carcinoma_real-world_data_from_the_USA_and_prospective_analysis_from_China/29003801
使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。
规范引用：Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China. Taylor & Francis. Li, Andong; Wu, Meiyu; Xie, Ouyang; Xiang, Heng; Meng, Kehui; Wan, Xiaomin
【使用注意】
· 源站最后修改于 2025-11-13，引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务（收技术服务费，非数据销售）
暂未开放当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取（Figshare）
- 源站标题：Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China
- DOI：10.6084/m9.figshare.29003801.v1
- 发布日期：2025-05-10
- 文件数：2 个
- 文件总体积：218.56 KB
- 源站页面：https://tandf.figshare.com/articles/dataset/Economic_evaluation_of_Erdafitinib_as_a_second-line_treatment_for_advanced_metastatic_urothelial_carcinoma_real-world_data_from_the_USA_and_prospective_analysis_from_China/29003801
命令行下载
curl -L -o "ifon_a_2504321_sm2014.docx" "https://ndownloader.figshare.com/files/54390596"
curl -L -o "ifon_a_2504321_sm1724.docx" "https://ndownloader.figshare.com/files/54390599"
文件清单
ifon_a_2504321_sm2014.docx（27.52 KB）ifon_a_2504321_sm1724.docx（191.04 KB）
文件总体积 218.56 KB（源站 API 实测）。
数据加载示例（图像类）
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
数据说明
Metastatic urothelial carcinoma (mUC) is challenging to treat, with 37% of patients failing first-line therapy. Effective second-line treatments, like Erdafitinib, are crucial. This study evaluates the cost-effectiveness of Erdafitinib as a second-line treatment for mUC from US and Chinese payer perspectives.
A Markov model was developed to project costs, life years, and quality-adjusted life years (QALYs) over lifetime. Data were collected from December 2023 to December 2024 for up-to-date estimates and were obtained from literature, health databases, and clinical trials… The model was run to project long-term outcomes for both the United States and China.
In the United States, Erdafitinib provides an additional 0.467 QALYs at a cost of $238,294.2 per QALY, which exceeds the $150,000 per QALY willingness-to-pay threshold. For China, when the cost of Erdafitinib is below $6.9 or $14 per milligram, there is a 90% probability that its incremental cost-effectiveness ratio will be below $38,223 or $84,966 per QALY, respectively.
From the perspective of U.S. payers, Erdafitinib as a second-line treatment for mUC is not cost-effective. From the perspective of China, the cost-effectiveness of Erdafitinib is highly sensitive to its price, which could provide a reference for healthcare reimbursement negotiations.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.6084/m9.figshare.29003801.v1（source: https://tandf.figshare.com/articles/dataset/Economic_evaluation_of_Erdafitinib_as_a_second-line_treatment_for_advanced_metastatic_urothelial_carcinoma_real-world_data_from_the_USA_and_prospective_analysis_from_China/29003801）。
数据缺失？
依托陕西、四川两大基地，我们与超过十家三甲医院建立直接合作关系，覆盖合规授权、采集治理、专业标注、数据交付的全流程，为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务？立即联系我们获取专业方案。
